TrialInternal medicine (Tokyo, Japan)2025
Effects of Ipragliflozin on Skeletal Muscle Adiposity in Patients with Diabetes and Metabolic Dysfunction-associated Steatotic Liver Disease.
Yuko Ishimaru et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.